Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EPS (Basic): 2017-2025

Historic EPS (Basic) for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$3.10.

  • Cidara Therapeutics' EPS (Basic) fell 26.53% to -$3.10 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.62, marking a year-over-year increase of 60.02%. This contributed to the annual value of -$26.82 for FY2024, which is 367.25% down from last year.
  • Per Cidara Therapeutics' latest filing, its EPS (Basic) stood at -$3.10 for Q3 2025, which was down 87.88% from -$1.65 recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' EPS (Basic) registered a high of $0.60 during Q1 2023, and its lowest value of -$20.65 during Q2 2024.
  • In the last 3 years, Cidara Therapeutics' EPS (Basic) had a median value of -$2.28 in 2024 and averaged -$3.78.
  • Within the past 5 years, the most significant YoY rise in Cidara Therapeutics' EPS (Basic) was 322.22% (2023), while the steepest drop was 1,362.50% (2023).
  • Quarterly analysis of 5 years shows Cidara Therapeutics' EPS (Basic) stood at -$0.28 in 2021, then spiked by 32.14% to -$0.19 in 2022, then crashed by 521.05% to -$1.18 in 2023, then plummeted by 256.78% to -$4.21 in 2024, then declined by 26.53% to -$3.10 in 2025.
  • Its last three reported values are -$3.10 in Q3 2025, -$1.65 for Q2 2025, and -$1.66 during Q1 2025.